Delivery Order SPE2DB20D2014-SPE2DB25FC10B
- Not listed
- The Defense Logistics Agency awarded a $15,814.20 delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyvanse 10 mg capsules (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 26, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,437.80 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) on August 7, 2025, with completion scheduled for August 8, 2025. This non-competitive, firm fixed-price delivery order represents a single pharmaceutical transaction under the company's existing indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Vyvanse 20 mg capsules (100-count units) with a ceiling value of $1,120.83. This firm fixed-price delivery order, with an ultimate completion date of August 5, 2025, represents a competitive award with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and is issued under the company's larger...
- The Defense Logistics Agency awarded a $1,269.13 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Vyvanse 10 mg capsules (100-count units) valued at $8,260.65. This firm fixed-price contract, with an ultimate completion date of August 21, 2025, represents a non-set-aside competitive award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a ceiling value of $1,100.64. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 19, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply transaction under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order valued at $2,174.23 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) on June 2, 2025, with an ultimate completion date of June 3, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) on July 23, 2025, with a ceiling value of $1,456.54 and an ultimate completion date of July 24, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a ceiling value of $2,943.88. This is a non-set-aside competitive award with a place of performance in Conshohocken, Pennsylvania, and an ultimate completion date of August 7, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $2,846.53 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 30 mg on August 28, 2025, with completion scheduled for August 29, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC10BDelivery Order
The Defense Logistics Agency awarded a $11,625.10 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Vyvanse 10 mg capsules (100-count units). This firm fixed-price contract represents a non-competitive set-aside delivery against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 3, 2025. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal military and healthcare procurement through its comprehensive DLA contract vehicle. The company supplies an extensive portfolio of pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order for Vyvanse, a controlled substance prescription medication, exemplifies the routine pharmaceutical distribution operations conducted under the global pharmaceutical support contract framework that enables flexible and efficient medical supply fulfillment across the federal healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.6k | 6/2/25 |